Startups & Venture Growth: Built at UCLA
- 226+ active companies built on UCLA technology
- From 2017 to 2024, UCLA launched 172 startups
Notable 2024 funding rounds:
- Cytovale raised $100M Series D for sepsis diagnostics
- Pictor Labs raised $30M Series B for AI-driven digital pathology
- Lyell Immunopharma acquired ImmPACT Bio USA, a UCLA cell therapy spinout (ImmPACT Bio was founded on the research of UCLA’s Yvonne Chen and Antoni Ribas)
Health & Clinical Impact: The Fight Against Cancer
8 FDA-approved cancer drugs developed at UCLA or pioneered by UCLA researchers:
- Herceptin (breast cancer) (3 million+ lives saved worldwide)
- Xtandi and Erleada (prostate cancer) (1.5 million+ men with advanced prostate cancer have benefited)
- Ibrance (breast cancer)
- Gleevec (leukemia)
- Kisqali (breast cancer)
- Keytruda (melanoma, lung cancer)
- Cyramza (lung, gastric and other cancers)
400+ active cancer clinical trials running at UCLA at any given time
Since 2014, UCLA Jonsson Comprehensive Cancer Center researchers have contributed to 22 FDA-approved cancer treatments/protocols
Sustainability & Community: Taking Care of You (and Our Planet)
- $800 million in new state funding for drinking-water fixes catalyzed by a UCLA analysis of system needs
- UCLA is tracking hundreds of millions of dollars in local climate-action investments. In Watts alone: 300 home energy upgrades, 261,000 pounds of fresh food delivered, and 2,250 trees planted
- New governance map covering 200+ water systems in L.A. County helps target infrastructure investments more efficiently.
Sources: University of California Technology Commercialization report (years 2023-2017) • UCLA Technology Development Group Innovation Magazine • UCLA Newsroom • UCLA Library (2023-2024 UCLA Library Impact Report) • UCLA Health Jonsson Comprehensive Cancer Center • National Cancer Institute • Beacon Economics • UCLA Luskin Center for Innovation
Credits:
Illustrations by Greg Mably